|Courtesy of Covidien|
What To Know: Much like Medtronic, Covidien ($COV) had to dig in its pockets to get into the renal denervation game, putting up $60 million up front plus a possible $170 million in milestones for Maya Medical, makers of the OneShot system. Unlike Medtronic, Covidien's device is a balloon catheter, inflating within renal arteries before administering its radio frequency ablation on sympathetic nerves. OneShot has had a quick rise to stardom, as Maya got a CE mark for the device in February, followed by Covidien buying the company in April and then hosting a big unveiling of the tech at May's EuroPCR conference in Paris.
What's Next: With its CE mark in hand, Covidien started clinical trials in Europe over the summer, and it is continuing to enroll patients. The company aims to launch the device overseas in the next 6 months, a spokesman said.
Release: Covidien unveils renal denervation device
Renal denervation devices wow EU docs
Crowded market could blunt profits for hypertension techs